This study describes the pharmacokinetics of a single subcutaneous dose of tramadol and shows that there were no differences in the rates of absorption or drug exposure between healthy subjects and patients. Although the pharmacokinetic profile of tramadol has previously been characterised in humans after oral, IM and IV administration, similar data have not been available for the SC route [
6‐
9]. While these data are frequently determined in healthy subjects they cannot always be extrapolated to sick patients, hence the importance of also documenting pharmacokinetics in this patient cohort [
22].
Tramadol is an atypical centrally acting analgesic agent which acts as both a mu-opioid receptor agonist and inhibitor of noradrenaline and serotonin reuptake. It is a racemic mixture where the (+) enantiomer preferentially inhibits serotonin reuptake and the (-) enantiomer preferentially inhibits noradrenaline reuptake [
23]. Tramadol is metabolised by O-demethylation to the active M1 and N-demethylation to the inactive M2 metabolites. Metabolism is dependent on the cytochrome P450 enzymes CYP2D6 and CYP3A4 [
23,
24]. M1 displays a 200-fold higher affinity for the mu-opioid receptor than the parent drug [
25]. Tramadol and its metabolites are almost completely excreted by the kidney [
23].
Tramadol is effective in the management of acute pain, although it may be inadequate for the management of moderate to severe acute pain if used as the sole analgesic agent [
1,
10]. When combined with morphine, tramadol is opioid-sparing, but the effect is infra-additive [
26]. Since tramadol is less likely to lead to respiratory depression and reduced gastrointestinal motility compared with pure opioid agonists at equianalgesic doses, it may be a useful choice in some patients such as those with respiratory compromise or obstructive sleep apnea, or those who have had gastrointestinal surgery [
1,
23,
27,
28]. Its effectiveness in the treatment of acute neuropathic pain may also make it a worthwhile agent in some patients [
29,
30].
Pharmacokinetics
While subcutaneous tramadol would not be of interest in mechanically ventilated critically ill patients where intravenous sedation and analgesia is a requirement, subcutaneous pain relief can be useful in spontaneously ventilating patients in a high dependency setting [
3,
4]. It may avoid the need for IV access and reduce the incidence of respiratory and gastrointestinal side effects when compared to IV administration [
2]. However, the pharmacokinetics of drugs cannot be presumed to be the same in severely ill patients as in healthy subjects. Trauma, the perioperative state and critical illness may affect drug absorption and distribution due to differences in skin perfusion and cardiac output. In a similar study investigating the pharmacokinetics of oxycodone after a single SC dose, marked differences were revealed between healthy subjects and a similar cohort of patients [
22]. The latter showed that AUC
0-∞, C
max and t½ were all significantly lower in the patient cohort despite no differences in t
max or MRT. In contrast, in this study of SC tramadol, no significant differences were found in AUC
0-∞ t½, t
max, C
max or MRT between patients and healthy subjects.
The SC pharmacokinetics of absorption of the following opioids has previously been reported: morphine in healthy subjects and older patients; fentanyl in healthy subjects; and oxycodone in both healthy subjects and critically ill patients [
22,
31‐
33]. The mean t
max values for tramadol in this study of 20.6 and 23.3 minutes in healthy subjects and patients, respectively, were comparable to those reported for oxycodone in both healthy subjects and critically ill patients (22.1 and 20.5 minutes respectively), but longer than that reported for fentanyl and morphine in subjects (both 15 minutes) or morphine in elderly patients (15.9 minutes).
In comparing the pharmacokinetic parameters of tramadol after oral, SC, IV and IM routes of administration in healthy subjects, our study using the SC route of 50 mg tramadol showed that the t
max was 20.6 minutes, t½ was 5.2 hours, C
max was 0.47 mcg/ml and AUC was 175 mcg/ml*min. Previous reports have shown that a 100 mg oral dose of tramadol in healthy subjects gave a t
max value of 66 minutes, a t½ value of 5.6 hours, a C
max value of 0.31 mcg/ml and an AUC value of 160 mcg/ml*min, whilst a single IV dose of 50 mg tramadol gave a t½ value of 5.5 hours, a C
max value of 0.35 mcg/ml and an AUC of 93 mcg/ml*min. With a single IM dose of 50 mg tramadol, the t
max was 45 minutes, t½ was 5.5 hours, C
max was 0.19 mcg/ml and the AUC was 95 mcg/ml*min [
9].
There are limited data on the urinary excretion of tramadol and its metabolites. In healthy subjects given a 50 mg oral dose of tramadol, the mean values for urinary excretion over 24 hours (expressed as a percentage of the dose administered) were tramadol 12%, M1 15%, and M2 4% [
34]. Following a 100 mg dose of oral tramadol, also given orally to healthy subjects, with urine collected over 30 hours, the mean values were 16.2% unchanged tramadol, 11.2% M1, and 1.1% M2 [
35]. Similar results were reported by Rudaz et al. also following administration of 100 mg oral tramadol to healthy subjects, again with urine collected over 30 hours: 16% unchanged tramadol, 16% M1 and 2.2% M2 [
36]. In our study, respective mean values were 28.2% tramadol, 4.01% M1 and 1.01% M2 in the urine collected over 10 hours in the healthy group. In the patient cohort, values were 24.3% tramadol, 3.43% M1 and 2.02% M2. Since the clearance via the M1 and M2 pathways does not appear to be different between the two groups (as assessed by the urinary metabolite to tramadol ratio), this suggests that the CYP2D6 (M1) and CYP3A4 (M2) pathways were not altered in severely ill patients.
The study was designed to avoid pharmacokinetic interactions with other drugs. In the patients fentanyl was chosen as the “rescue” opioid, delivered by PCA, for intercurrent pain relief because it is metabolised by the cytochrome P450 enzyme CYP3A4. CYP3A4 is also responsible for metabolism of tramadol to M2. However, fentanyl is only a substrate and not an inducer/inhibitor of CYP3A4 at therapeutic concentrations. If fentanyl was competing with tramadol as a substrate for this enzyme, the AUC0-∞ results for tramadol would have been higher in the patients who were receiving fentanyl. Two of the patients received oral oxycodone during the study period. Oxycodone is metabolised by CYP3A4 and CYP2D6. Similarly, oxycodone is only a substrate and not known to be an inhibitor of CYP2D6, and therefore the results from these patients were not excluded.
A possible limitation of this study is the mismatching between the group in terms of age and sex. However given that no difference was noted in the pharmacokinetics between the groups it is unlikely that the results of the study would have been different if the groups had been better matched. Based on the paucity of pharmacokinetic data after SC administration of this drug, no a priori power calculation was performed, which is therefore one of the limitations of this study. Hence, between-group differences in some pharmacokinetic parameters, found to be similar in this study, cannot be confidently excluded as the study may not have been adequately powered to demonstrate a difference. Nevertheless, there is no trend for a difference in any parameter so any possible difference is likely to be small and may not be clinically relevant. The estimated effect size and its standard error are given in Table
2 to indicate the study power. Moreover, there may be some patient groups where the time-course of drug concentrations and effect are clinically different from the patients in the current study. We chose not to phenotype our subjects for CYP2D6, because total subject numbers would have been too small to detect significant differences.